Cardarine GW-501516

10mg per capsule · 90 capsules

£44.99

In stock · Order before 2pm for next-day dispatch

Purity≥99% (HPLC verified)

Active ingredient10mg per capsule

Count90 capsules

ManufacturerUK — ISO certified

Overall research score

7.5 / 10

Good · Unmatched endurance research — not a SARM, no hormonal suppression

Metric breakdown

Endurance research 9.8

Fat oxidation 9.2

Safety profile 6.0

Bioavailability 8.5

Research depth 7.5

Suppression risk Low

Hepatotoxicity Minimal

Compound profile

Chemical name: 2-[2-Methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid
Molecular weight: 453.47 g/mol
Half-life: 16–24 hours
Detection time: Not established
Research active: 10–20mg / day
Research cycle: 6–8 weeks
CAS number: 317318-70-0

Research applications

Endurance research Fat oxidation Metabolic research Non-suppressive Advanced use only

Research use only. Scores derived from published preclinical and peer-reviewed literature. Not intended for human consumption.

Description

What Is GW-501516 (Cardarine)?

GW-501516 (Cardarine) is an investigational compound studied in PPAR-delta pathway research. This page provides a practical research reference overview with mechanism context, evidence limits, handling notes, and batch verification standards.

Compound Profile

Name	GW-501516 (Cardarine)
CAS	317318-70-0
Formula	C21H18F3NO3S2
Molecular Weight	453.50 g/mol
Category	Investigational PPARδ agonist (not a SARM)
PubChem	9803963

What is gw-501516 cardarine is a common query used by researchers separating PPAR-pathway compounds from AR-modulating compounds.

How Does GW-501516 Work?

Published work describes GW-501516 as a PPARδ agonist evaluated for metabolic and endurance-related pathway signalling in model systems. This page is technical reference content, not therapeutic guidance.

Researchers often compare gw-501516 vs sarms research when differentiating mechanism classes and endpoint interpretation.

What Does Current Research Say?

Preclinical literature includes metabolism, mitochondrial, and endurance pathway discussions.
Evidence quality varies by model, duration, and endpoint type.
No broad consumer therapeutic approval exists.
Interpretation should prioritize study design and method quality.

Typical search intent includes gw-501516 dosage research use and gw-501516 cycle length research phrasing, which should be read as literature context rather than user instruction.